CA2928773A1 - Cell transport - Google Patents

Cell transport Download PDF

Info

Publication number
CA2928773A1
CA2928773A1 CA2928773A CA2928773A CA2928773A1 CA 2928773 A1 CA2928773 A1 CA 2928773A1 CA 2928773 A CA2928773 A CA 2928773A CA 2928773 A CA2928773 A CA 2928773A CA 2928773 A1 CA2928773 A1 CA 2928773A1
Authority
CA
Canada
Prior art keywords
cpp
agent
therapeutic
molecule
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2928773A
Other languages
English (en)
French (fr)
Inventor
William Jonathan RYVES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CUPID PEPTIDE Co Ltd
Original Assignee
CUPID PEPTIDE COMPANY LIMITED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CUPID PEPTIDE COMPANY LIMITED filed Critical CUPID PEPTIDE COMPANY LIMITED
Publication of CA2928773A1 publication Critical patent/CA2928773A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2928773A 2013-10-28 2014-10-09 Cell transport Pending CA2928773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1318954.3 2013-10-28
GBGB1318954.3A GB201318954D0 (en) 2013-10-28 2013-10-28 Cell transport
PCT/GB2014/053037 WO2015063452A2 (en) 2013-10-28 2014-10-09 Cell transport

Publications (1)

Publication Number Publication Date
CA2928773A1 true CA2928773A1 (en) 2015-05-07

Family

ID=49767211

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928773A Pending CA2928773A1 (en) 2013-10-28 2014-10-09 Cell transport

Country Status (6)

Country Link
US (1) US9913914B2 (enExample)
EP (1) EP3062822B1 (enExample)
JP (1) JP6576355B2 (enExample)
CA (1) CA2928773A1 (enExample)
GB (1) GB201318954D0 (enExample)
WO (1) WO2015063452A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014190A1 (en) 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF
EP3652195A4 (en) 2017-07-10 2021-08-04 SRI International PEPTID-SAPORINE CONJUGATE FOR THE TREATMENT OF CANCER
EP3820494A4 (en) * 2018-07-13 2022-07-13 The Trustees of Princeton University SYSTEM AND METHOD FOR MODULATION OF A STRESS GRANULE ASSEMBLY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523359A (en) * 1995-01-13 1996-06-04 Exxon Chemical Patents Inc. Functionalized polymer and methods to obtain functionalized polymer
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
ES2318906T3 (es) 1998-11-13 2009-05-01 Cyclacel Limited Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia.
US7091026B2 (en) * 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
GB0229151D0 (en) * 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
US20050112064A1 (en) * 2003-08-12 2005-05-26 Sonya Franklin DNA-dependent MRI contrast agents
JP5295785B2 (ja) * 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
WO2007109908A1 (en) * 2006-03-29 2007-10-04 The University Of British Columbia Therapeutic yb-1 phosphorylation decoys
WO2012023284A1 (en) 2010-08-20 2012-02-23 Oncotherapy Science, Inc. Lhx4 as a target gene for cancer therapy and diagnosis
WO2012170431A2 (en) 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems

Also Published As

Publication number Publication date
GB201318954D0 (en) 2013-12-11
EP3062822A2 (en) 2016-09-07
JP6576355B2 (ja) 2019-09-18
WO2015063452A2 (en) 2015-05-07
US20160310607A1 (en) 2016-10-27
JP2016535600A (ja) 2016-11-17
US9913914B2 (en) 2018-03-13
EP3062822C0 (en) 2025-05-14
WO2015063452A3 (en) 2015-09-17
EP3062822B1 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
Wang et al. Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
Deshayes et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy
Futaki et al. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization
Ruczynski et al. Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells
US10131888B2 (en) Intracellular protein delivery
AU2021200135A1 (en) Liposome compositions and methods of use thereof
US9969774B2 (en) Cell penetrating peptide and method for delivering biologically active substance using same
JP2014159484A (ja) 細胞透過のための過剰に荷電されたタンパク質
JP2011523353A5 (enExample)
EP2928907A1 (en) Cell penetrating peptides for intracellular delivery of molecules
JP2011137001A (ja) ポリヌクレオチドを送達する方法、及び送達用組成物
Noguchi et al. Macropinocytosis-inducible extracellular vesicles modified with antimicrobial protein CAP18-derived cell-penetrating peptides for efficient intracellular delivery
CN101395180A (zh) 用作细胞穿膜肽的肽
CN102458439A (zh) 包含抗真菌肽的药物组合物
US20210269504A1 (en) Protein-based micelles for the delivery of hydrophobic active compounds
US9913914B2 (en) Cell transport
JP7276895B2 (ja) 遺伝子発現抑制剤
KR20150130249A (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
CN113966233A (zh) 用于基因编辑的细胞膜穿透缀合物
Zhang et al. Stearylated antimicrobial peptide [D]-K6L9 with cell penetrating property for efficient gene transfer
US20240092837A1 (en) Novel Peptide Carrier Compositions
Cahill Cell-penetrating peptides, electroporation and drug delivery
EP4475889A1 (en) Protein carrier system based on cyanobacterial nano-sized extracellular vesicles
US12404307B2 (en) Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
KR102114842B1 (ko) 세포 투과형 염기성섬유아세포성장인자를 함유하는 피부 생리활성 피부외용제 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190912

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240924

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240924

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240924

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250327

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250328

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20250728

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260409

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703